UPDATE: BofA Securities Upgrades Prothena Corp (PRTA) to Neutral

June 18, 2021 6:06 AM EDT
Get Alerts PRTA Hot Sheet
Price: $54.10 +2.58%

Rating Summary:
    16 Buy, 2 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 22 | Down: 13 | New: 31
Trade Now! 
Join SI Premium – FREE
(Updated - June 18, 2021 7:14 AM EDT)

BofA Securities upgraded Prothena Corp (NASDAQ: PRTA) from Underperform to Neutral with a price target of $49.00.

The analyst comments "Competitor AB program Aduhelm (aducanumab) by BIIB (covered by Geoff Meacham) was recently approved for AD on its June 7th PDUFA date. Recall PRTA’s early stage asset, PRX012, is an AB antibody similar to adu’ however ‘012 has shown up to 10x higher potency vs adu’ in preclinical studies potentially making SC administration possible (adu’ is administered via IV infusion). We revisit our valuation for PRTA given similar MoA and ‘012 has shown a superior profile in preclinical studies. While we normally do not model stand-alone value for preclinical assets, we recognize that adu’s accelerated approval based on amyloid reduction bodes positively for ‘012."

For an analyst ratings summary and ratings history on Prothena Corp click here. For more ratings news on Prothena Corp click here.

Shares of Prothena Corp closed at $48.72 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, Upgrades

Related Entities

PDUFA